The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.
A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback